CYP19A1 and endometriosis: Similar to anastrozole and letrozole, third-generation aromatase inhibitors, which selectively inhibit the action of aromatase, have been investigated for the treatment of endometriosis as monotherapy or in combination with other hormonally active drugs (Ferrero et al., 2018).